Rocket Pharmaceuticals, Inc. Cash and Cash Equivalents
Rocket Pharmaceuticals, Inc. (RCKT) had Cash and Cash Equivalents of $224.51 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-10
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $224.51M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $49.61M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $77.56M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $75.95M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $224.51M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $49.61M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $77.56M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $75.95M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $32.82M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $49.81M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $163.63M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $65.60M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $38.61M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $35.28M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $55.90M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $225.66M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $45.08M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $64.58M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $140.52M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $196.67M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $187.55M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $130.55M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $232.69M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $245.64M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $264.61M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $252.54M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $297.10M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $82.23M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $163.20M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $190.52M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $185.38M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $89.19M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $64.83M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $124.46M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $111.36M 10-K · filed 2020-03-06 | |
| 2018-09-30 | $38.08M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $52.55M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $171.14M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $18.14M 10-K · filed 2019-03-08 | $78.72M 10-K · filed 2018-03-07 |
| 2017-09-30 | $49.15M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $27.61M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $25.27M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $29.80M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $83.00M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $38.52M 10-Q · filed 2017-08-03 | |
| 2016-03-31 | $58.71M 10-Q · filed 2017-05-10 | |
| 2015-12-31 | $80.04M 10-K · filed 2018-03-07 | |
| 2015-09-30 | $89.25M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $49.01M 10-Q · filed 2016-08-10 | |
| 2015-03-31 | $53.14M 10-Q · filed 2016-05-11 | |
| 2014-12-31 | $3.62M 10-K · filed 2017-03-16 | |
| 2014-09-30 | $5.36M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $8.88M 10-Q · filed 2015-08-07 | |
| 2014-03-31 | $10.94M 10-Q · filed 2015-05-14 | |
| 2013-12-31 | $12.79M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |